anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Obesity is a known risk factor for developing rheumatoid arthritis (RA). However, it is unclear whether obesity exerts its risk effect during the asymptomatic or the symptomatic clinically suspect arthralgia (CSA) phase of risk. To improve understanding of the effect of obesity on RA development, we aimed to (1) compare body mass index (BMI) at CSA onset to BMI of the general population and (2) study within CSA patients if obesity increases the risk for progression to RA.
METHODS: 1107 symptomatic persons at risk for RA from four cohorts (CSA Leiden, CSA Rotterdam, SONAR and TREAT EARLIER placebo arm) were studied. For the first aim, baseline BMI was compared with age-matched/sex-matched BMI of the general population. Patients were stratified for anticitrullinated protein antibody (ACPA) status. Regarding the second aim, the association between BMI and inflammatory arthritis (IA) development during 2 years was studied with Cox regression analysis within each cohort and via meta-analysis in all cohorts.
RESULTS: CSA patients of all cohorts were more often obese than the general population (respectively 21.9% vs 14.0%, 25.7% vs 14.5%, 26.7% vs 14.5% and 33.3% vs 14.9%, in CSA Leiden, CSA Rotterdam, SONAR, TREAT EARLIER placebo arm). Both ACPA-positive and ACPA-negative CSA patients had a higher frequency of obesity. Within CSA, obesity was not associated with IA development compared to normal weight (pooled effect in meta-analysis of four cohorts HR 1.01 (95% CI 0.93 to 1.08)).
CONCLUSIONS: Obesity is not associated with RA development within CSA patients but BMI has already increased in CSA compared to the general population. Obesity, therefore, presumably exerts its risk effect at an early asymptomatic phase of RA development, rather than being associated with the disease processes that ultimately result in clinical arthritis.
The present invention relates to a Chinese patent medicine of a capsule of regulating a stomach and lowering adverse flow of qi (an original name: weiyankang or weikang) and a preparation technology. An original technique comprises: the morbidity of chronic atrophic gastritis is from 7% to 15%; in patients with the atrophic gastritis, patients who have intestinal glandular epithelium metaplasia and atypical hyperplasia account for a large proportion; medicine for treating the intestinal glandular epithelium metaplasia and the atypical hyperplasia does not have a basic therapeutic proposal in China. The goal of the present invention is to make up for a therapeutic advantage which is not contained in other Chinese patent medicines for better satisfying a medical requirement. The capsule of regulating a stomach and lowering adverse flow of qi comprises Chinese herbal medicines, such as shaqi, fibraurea recisa, old dragon peel, creeping chilopod rhizome, iron ocher and dandelion to form a compound. The preparation technology can select a conventional technology. The Chinese patent medicine has the advantages of the functions of promoting blood circulation, regulating qi, clearing heat, removing stasis, regulating a stomach and lowering adverse flow of qi, convenient administration, reasonable preparation and obvious therapeutic effect. Through 518 examples of CAG clinical therapy, a symptom effective rate is 98.64% and the total effective rate of pathology is 83.04%. Indicated by a pharmacodynamic test, the medicine does not have obvious toxic side effect.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of further stabilizing a solid drug preparation for internal use comprising a benzimidazole-based compound by formulating the benzimidazole-based compound and a specific substance. SOLUTION: This composition is obtained by formulating (A) a benzimidazole- based compound of formula I (Het1 is of formula II; Het2 is of formula III; R1 and R2 are each H, methoxy or difluoromethoxy; R3 is H or sodium, R4 to R6 are each H, methyl, methoxy, methoxypropoxy or trifluoroethoxy) (e.g. rabeprazole of formula IV) with (B) a substance selected from e.g. a sodium carbonate, sodium hydroxide, potassium hydroxide, crospovidone, at preferably 0.01-20 pts.wt per pt.wt. of the ingredient A. It is also possible to make a drug preparation by coating a core composed of the above composition with an intermediate film, enteric film or moistureproof film.
Acute kidney injury (AKI) is a common complication during critical illness and associated with serious short and long-term complications. Participants with AKI have an increased risk of developing dysfunction of other organs, including multi-organ failure, a longer stay in hospital and a higher risk of dying. Survivors remain at risk of complications, even if kidney function initially recovers. In particular, they are at high risk of developing chronic kidney disease, dialysis-dependent end-stage kidney disease and cardiovascular comorbidities. At present, the tools to identify patients at highest risk of chronic kidney disease (CKD) are very limited.

The investigators will recruit participants who had AKI whilst in ICU and are scheduled to be discharged from hospital. Within 3 days of discharge from hospital, blood and urine kidney biomarkers will be measured to explore whether there is a correlation with renal function 3 months later and to identify those at highest risk of CKD. In addition, quality of life at 3 months will be assessed.
This study is a randomized, double-blinded, and placebo controlled phase III clinical trial in in adults aged 18\~59 Years. The study was planned as a multicenter, randomized controlled, double-blind, parallel-arm drug study. The purpose of this study is to evaluate the efficacy and safety of hydroxychloroquine, favipiravir, or hydroxychloroquine + favipiravir treatments that were initiated early in patients who were caught during filiation or who were decided to be outpatient due to mild disease findings during hospital admission, after the diagnosis of COVID-19 against patients with placebo. It is planned that the study will be conducted with two separate arms. Study arms are planned as 2:2:2:1 for 320:320:320:160 patients as follows. The dose of Favipiravir has been determined as the standard dose. Hydroxychloroquine will also be given without a loading dose.
Patients undergo MRI before and after gadolinium contrast administration, including 3D volumetric T1-weighted sequence, FLAIR sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also analyzed for the tumor genetic profile.
The recurrence of colorectal liver metastasis (CRLM) following liver resection is common; approximately 40% of patients will experience tumor recurrence post-surgery. Renin-angiotensin inhibitors (RASis) have been shown to attenuate the growth and progression of CRLM in pre-clinical models following liver resection. This study examined the efficacy of the RASi captopril on patient-derived colorectal liver metastasis organoids. Patient-derived organoids (PDOs) were established using fresh samples of colorectal liver metastasis from appropriately consented patients undergoing liver resection. To mimic the regenerating liver post-CRLM liver resection, PDOs were cultured under hepatocyte regeneration conditions in vitro. CRLM PDOs were established from three patients' parent tissue. CRLM PDOs and parent tissue expressed markers of colorectal cancer, CDX2 and CK20, consistently. Furthermore, CRLM PDOs treated with captopril showed a dose dependent reduction in their expansion in vitro. In conclusion, CRLM PDOs recapitulate in vivo disease and displayed a dose-dependent response to treatment with captopril. RASis may be an additional viable treatment for patients with CRLM.
OBJECTIVES: To determine whether the age at menarche (AAM) and the age at menopause (ANM) are causally related to the development of sepsis.
METHODS: We performed a two-sample Mendelian randomization (MR) analysis by utilizing summary statistics from genome-wide association study (GWAS) datasets for both the exposure and outcome variables. Single nucleotide polymorphisms (SNPs) that exhibited significant associations with AAM and ANM were chosen as instrumental variables to estimate the causal effects on sepsis. Our study employed a variety of methods, including MR-Egger regression, weighted median estimation, inverse variance weighting, a simple model, and a weighted model. Odds ratios (ORs) along with their corresponding 95% confidence intervals (CIs) were used as the primary indicators for assessing causality. Furthermore, we conducted sensitivity analyses to explore the presence of genetic heterogeneity and validate the robustness of the tools employed.
RESULT: Our analysis revealed a significant negative causal relationship between AAM and the risk of sepsis (IVW: OR = 0.870, 95% CI = 0.793-0.955, P = 0.003). However, our Mendelian randomization (MR) analysis did not yield sufficient evidence to support a causal link between ANM and sepsis (IVW: OR = 0.987, 95% CI = 0.971-1.004, P = 0.129).
CONCLUSIONS: Our findings suggest that an earlier AAM may be associated with an increased risk of sepsis. However, we did not find sufficient evidence to support a causal relationship between ANM and sepsis.
PURPOSE:A composition for dermatologic administration containing at least one selected from dried bark of phellodendoron amurense RUPRECUT of the family Rutaceae and dried rhizome of Coptis Japonica MAKINO of the family Ranunculaceae and the dried whole plant of Chelidonium majus L. subsp. asoaticum HARA of the family Papaveraceae. CONSTITUTION:At least one of dried bark of Phellodendoron amurense RUPRECUT of the family Rutaceae and dried rhizome of coptis Japonica MAKINO of the family Ranunculaceae is blended with the dried whole plant of Chelidonium majus L. subsp. asoaticum HARA of the family Papaveraceae in a weight ratio of 1:10, preferably 1:2- 4 to give a composition for dermatologic administration to be added to a remedy for skin diseases, bothing agent, shampoo, soap, etc. An amount of each component in a base, etc. is 0.01-20wt% in case of dried powder of the whole plant of Chelidonium majus L. subsp. asoaticum HARA of the family Papaveraceae, 0.003-10wt% in case of extract of it, 0.01-10wt% in case of dried powder of dried bark of Phellodendoron amurense RUPRECUT of the family Rutaceae, 0.003-5wt% in case of extract of it, and an amount of dried rhizome of coptis Japonica MAKINO of the family Ranunculaceae is almost the same as that of dried bark of Phellodendoron amurense RUPERCUT of the family Ranunculaceae. A dose for remedy for trauma, humid tetter, etc. is 50-200mg in case of powder, and 5-20mg in case of extract.
Long noncoding RNA nuclear-enriched abundant transcript 1 (NEAT1) is involved in the progression of Parkinson's disease (PD), but the specific regulatory role needs further exploration. This study showed that the expression of NEAT1 was upregulated in the cerebrospinal fluid (CSF) and peripheral blood of patients with different stages of PD. 1-Methyl-4-phenylpyridine (MPP)-treated PC 12 cells were transfected with si-NEAT1, and MPP treatment promoted cell apoptosis, oxidative stress and inflammatory factor secretion. Si-NEAT1 reversed the effects of MPP. NEAT1 silencing eliminated the effect of MPP on the protein expression levels of LC3-II and p62/SQSTM1. By using an online bioinformatics database, Fused in Sarcoma (FUS) was confirmed to be an RNA binding protein of NEAT1, and it was highly expressed in the CSF and peripheral blood of patients with PD. Si-FUS was transfected into MPP-treated PC 12 cells to detect cell apoptosis, oxidative stress, inflammatory factor secretion and autophagy, and the results were the same as those of transfection of si-NEAT1. Furthermore, MPP treatment reduced the phosphorylation levels of PI3K, Akt and mTOR, whereas si-FUS reversed the effects of MPP. In vivo, compared with the model group, the PD mice showed reduced NEAT1 and FUS expression levels and activated PI3K pathway after being injected with si-NEAT1. The brain tissue of NEAT1-silenced PD mice had decreased inflammatory infiltration and apoptosis and increased neurological scores. In conclusion, NEAT1 is involved in PD progression through FUS-mediated inhibition of the PI3K/AKT/mTOR signalling pathway.
An edible healthy gelatin crystal and the preparation method thereof belong to the field of Chinese healthy product processing technology. The edible healthy gelatin crystal is prepared from one, two, three, or four of preprocessed donkey skin, deer horn, velvet and turtle shell as main materials or from one, two or three of donkey-hide gelatin, deer-horn gelatin and turtle shell gelatin as main materials by soaking in water, cutting into small pieces, decocting with water, filtering, reducing water to 20 to 35% by concentration with slow fire to obtain gelatin paste for standby, adding adjuvant, cooling, shaping, and drying in the shade to obtain the product. Based on the prior pharmaceutical technology, the invention can prepare a directly-edible functional food mainly containing donkey-hide gelatin, deer-horn gelatin, velvet, turtle shell gelatin, etc. by decocting animal skin, bone, shell or horn with water to obtain gelatin or drying the gelatin, and adding plasticizer and other additional components. The functional food can be made into 'soft capsule' that can be applied directly, and has simple and practical preparation process and convenient usage. The soft capsule preparation has the advantages of convenient usage, good portability and wide application range, and can be taken orally, swallowed directly or applied externally.
During the last decade, there has been a move towards consumer-centric hearing healthcare. This is a direct result of technological advancements (e.g., merger of consumer grade hearing aids with consumer grade earphones creating a wide range of hearing devices) as well as policy changes (e.g., the U.S. Food and Drug Administration creating a new over-the-counter [OTC] hearing aid category). In addition to various direct-to-consumer (DTC) hearing devices available on the market, there are also several validated tools for the self-assessment of auditory function and the detection of ear disease, as well as tools for education about hearing loss, hearing devices, and communication strategies. Further, all can be made easily available to a wide range of people. This perspective provides a framework and identifies tools to improve and maintain optimal auditory wellness across the adult life course. A broadly available and accessible set of tools that can be made available on a digital platform to aid adults in the assessment and as needed, the improvement, of auditory wellness is discussed.
The sprint performance was determined by various relevant factors, and they were mainly divided into central system factor and peripheral system factor. An effective sprint start requires a quick reaction to an auditory stimulus followed by a determined sequence of activation of particular muscles responsible for maximum movement speed. Both of the skill-related physical fitness, including muscle strength, muscle endurance, muscle power, speed, agility, and balance, and muscle physical characteristic, including muscle tone and muscle architecture, are related to the sprint performance. The 100m race could divided into three different phases, start acceleration, maximum speed, and deceleration. According to Collet, 1999, the determinants of the temporal structure of the sprint start are RT, movement speed and movement frequency, which involves in perfecting sprinters' physical performance. And also, according to Pilianidis et al., 2012; Tonnessen et al., 2013, the start reaction time significantly affects the reduction of running time in 100 m races. In the recent studies, there are researches only showing that the auditory stimulus trainings significantly affected the final results for swimming athletes, and that the visual stimulus trainings significantly affected the final scores for badminton athletes.This study will mainly recruit the healthy adolescent athletes of the athletics sprint and other kinds of sports in the age range 13-18 years, and will evaluate the athletes of anthropometric measurements and physical fitness, 100m sprint performance, muscle characteristic, jump ability, agility, and nerve potential measurements.The outcome of this study will be able to be one of the comprehensive trials for coaches to take into consideration when choosing their own athletes. And also, the athletes may choose their own specialties that fit their own physical conditions. Moreover, the adolescent athletes will be trained more precisely and effectively. These will positively lead to reaching their personal best results and decreasing the occurrences of the sport injuries due to unsuitable events and trainings.
PURPOSE:To provide a soft capsule comprising an edible capsule coating film not containing an animal protein and capable of being easily dissolved, high in safety, and used for medicines and foods. CONSTITUTION:Three kinds of components comprising an edible polymeric substance (e.g. alginic acid) which can easily be dissolved in water, whose 1% aqueous solution has a viscosity of <=1000 cps at 70 deg.C, and which does not contain an animal protein as a film-forming base agent, an agar and/or a low mol. wt. agar having a jelly strength of <=300g/cm<2> a gelled filmforming base agent, and a plasticizer (e.g. glycerol) are-combined with each other to provide a soft capsule coating film-forming material. The soft capsule coating film-forming material is prepared into a soft capsule by a dropping method. By the method, a capsule content solution and the capsule coating film-forming material solution are extruded from an inside extrusion nozzle and an outside extrusion nozzle, respectively, among the nozzles of a triple or double structure into an oily liquid at a constant rate with a pump or the gravity, and the extruded solution is cut at a constant distance by some physical force such as vibration, impact or the difference between the flow rates of the capsule solution and the oily liquid, thus forming spherical soft capsules each having a diameter of 0.3-20mm by the interfacial tension between the oily liquid and the capsule coating film-forming solution.
BACKGROUND: Sleep plays an important role in children's behavior, emotional control, and cognitive development. There is a higher prevalence of sleep problems in children with neurodevelopmental disorders (NDDs) compared to those without disease. There are a few studies regarding sleep problems among Thai preschoolers with NDDs. This study examined sleep problems in preschoolers with NDDs, compared with typically developing children (TD), and studied the association between sleep problems and behavioral problems among preschoolers with NDDs.
METHODS: Sleep problems in 140 children aged 2 to 6 years with NDDs; autism spectrum disorders, attention deficit/hyperactivity disorder, global developmental delay, and developmental language disorder were evaluated by using the Thai version of Japanese Sleep Questionnaire for Preschoolers (TH-JSQ-P) and compared with 285 TD children at the same age. Behavioral problems in the NDDs group were evaluated by using the Child Behavioral Checklist (CBCL). Sleep and behavioral problem scores were analyzed by adjusted age, sex, underlying diseases, and medications used and compared between the two groups.
RESULTS: The study found that 48 % of the TD group and 71 % of the NDDs group were identified as having sleep problems. The NDDs group had significantly higher total TH-JSQ-P score and in five subscales, including obstructive sleep apnea, restless leg syndrome-motor, parasomnias, daytime behaviors, and insomnia/circadian rhythm disorders. Total TH-JSQ-P score was found to have a moderate correlation with internalizing and externalizing behavioral problems.
CONCLUSION: Findings suggest that sleep problems are more common in preschool children with NDDs than in TD children and are associated with internalizing and externalizing behavioral problems.
The CG will receive basic education on stroke caregiving, as research indicates that basic education is not effective in improving problem-solving coping abilities and depressive symptoms. Four weekly individual stroke education (60 minutes/session) will be conducted by a trained research nurse. It will be based on a developed information booklet for local stroke caregivers. The participants will received three biweekly phone calls for general greetings. Questions relating to stroke caregiving raised by the caregivers will be answered according to the educative content. Any extra information provided will be documented.
There are currently few safe and effective methods for restoring lost bone to the osteoporotic skeleton. Therefore, prevention of osteoporosis is crucial. If skeletal development can be maximized during growth, young people will begin adulthood with optimal bone mass and will be less likely to develop osteoporosis in later years. This study will determine the effects of weight-bearing physical activity and a high-calcium diet on bone mass in adolescent girls.

Participants in this study will be randomized to one of three study arms. Girls in Arm 1 will consume their usual diets and will participate in a weight-bearing exercise program that meets 3 times per week. Girls in Arm 2 will also participate in a weight-bearing exercise program that meets 3 times per week and will be given high calcium foods to supply 1500 mg of calcium per day. Girls in Arm 3 will consume their usual diet and maintain their customary activity level. Study visits occur every 6 months; participants will be followed for 4 ½ years. Assessments will include a medical and social history and measurements of spine, hip, radius, and total body bone mineral content (BMC); calcaneal speed of sound (SOS); height; weight; and Tanner stage.
Over the last decade, multiple studies have shown that hearing-impaired listeners' speech-in-noise reception ability, measured with audibility compensation, is closely associated with performance in spectro-temporal modulation (STM) detection tests. STM tests thus have the potential to provide highly relevant beyond-the-audiogram information in the clinic, but the available STM tests have not been optimized for clinical use in terms of test duration, required equipment, and procedural standardization. The present study introduces a quick-and-simple clinically viable STM test, named the Audible Contrast Threshold (ACT™) test. First, an experimenter-controlled STM measurement paradigm was developed, in which the patient is presented bilaterally with a continuous audibility-corrected noise via headphones and asked to press a pushbutton whenever they hear an STM target sound in the noise. The patient's threshold is established using a Hughson-Westlake tracking procedure with a three-out-of-five criterion and then refined by post-processing the collected data using a logistic function. Different stimulation paradigms were tested in 28 hearing-impaired participants and compared to data previously measured in the same participants with an established STM test paradigm. The best stimulation paradigm showed excellent test-retest reliability and good agreement with the established laboratory version. Second, the best stimulation paradigm with 1-second noise "waves" (windowed noise) was chosen, further optimized with respect to step size and logistic-function fitting, and tested in a population of 25 young normal-hearing participants using various types of transducers to obtain normative data. Based on these normative data, the "normalized Contrast Level" (in dB nCL) scale was defined, where 0 ± 4 dB nCL corresponds to normal performance and elevated dB nCL values indicate the degree of audible contrast loss. Overall, the results of the present study suggest that the ACT test may be considered a reliable, quick-and-simple (and thus clinically viable) test of STM sensitivity. The ACT can be measured directly after the audiogram using the same set up, adding only a few minutes to the process.